State of New Jersey Common Pension Fund D Has $1.89 Million Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

State of New Jersey Common Pension Fund D decreased its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 13.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 42,593 shares of the biopharmaceutical company’s stock after selling 6,350 shares during the period. State of New Jersey Common Pension Fund D owned 0.07% of Agios Pharmaceuticals worth $1,892,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Farallon Capital Management LLC lifted its holdings in shares of Agios Pharmaceuticals by 1.1% during the 2nd quarter. Farallon Capital Management LLC now owns 5,654,502 shares of the biopharmaceutical company’s stock valued at $243,822,000 after buying an additional 63,900 shares during the last quarter. Vanguard Group Inc. grew its position in Agios Pharmaceuticals by 0.8% in the first quarter. Vanguard Group Inc. now owns 5,572,021 shares of the biopharmaceutical company’s stock worth $162,926,000 after acquiring an additional 44,583 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Agios Pharmaceuticals by 23.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,012,993 shares of the biopharmaceutical company’s stock worth $58,861,000 after purchasing an additional 388,381 shares during the last quarter. Marshall Wace LLP raised its holdings in shares of Agios Pharmaceuticals by 307.8% during the 2nd quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company’s stock valued at $48,887,000 after purchasing an additional 855,739 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. boosted its holdings in Agios Pharmaceuticals by 66.7% in the second quarter. Frazier Life Sciences Management L.P. now owns 871,974 shares of the biopharmaceutical company’s stock worth $37,600,000 after purchasing an additional 348,808 shares in the last quarter.

Insider Transactions at Agios Pharmaceuticals

In other news, CFO Cecilia Jones sold 2,542 shares of the business’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the sale, the chief financial officer now directly owns 20,158 shares in the company, valued at approximately $988,346.74. The trade was a 11.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 4.93% of the company’s stock.

Agios Pharmaceuticals Price Performance

NASDAQ:AGIO opened at $52.89 on Tuesday. Agios Pharmaceuticals, Inc. has a one year low of $20.96 and a one year high of $62.58. The company has a fifty day moving average price of $46.62 and a 200 day moving average price of $44.07. The stock has a market cap of $3.02 billion, a P/E ratio of 4.66 and a beta of 0.75.

Analyst Ratings Changes

AGIO has been the subject of a number of analyst reports. Raymond James reaffirmed an “outperform” rating and issued a $51.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, October 10th. Leerink Partnrs cut Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 27th. Royal Bank of Canada reissued an “outperform” rating and issued a $55.00 price target on shares of Agios Pharmaceuticals in a research report on Friday, November 1st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. Finally, Leerink Partners downgraded shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $60.00 to $56.00 in a report on Friday, September 27th. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Agios Pharmaceuticals has an average rating of “Hold” and a consensus target price of $52.33.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.